At the Human Health Therapeutics Research Centre, our mission to accelerate innovative biologics in Canada starts at the discovery stage. We work with clients and collaborators to design complex early-stage biologics for treating or preventing chronic diseases and emerging infections.
We have expertise in R&D throughout the discovery stage:
- Target identification with proprietary databases
- Traditional and single-domain antibody generation and characterization
- Viral vector design and targeting
- Cell therapy and immunotherapy platforms
- Antimicrobial alternatives
- Vaccine development
- Analytical development
- Biophysical characterization
Research areas
Expression systems: Cell line development and protein and viral vector production in animal cells
- HEK293SF-3F6 and HEK293-6E expression platforms
- CHO expression platform
- A549 expression system to produce adenoviral vectors
Antibodies: Antibody generation, antibody characterization and lead optimization using antibodies alone or to target other therapeutics such as chimeric antigen receptor T‑cells (CAR-T cells) or lipid nanoparticles
- Multi-Functional Antibody-Based Therapeutics Research program
- Disruptive Technology Solutions for Cell and Gene Therapy Challenge program
Vectors: Improvements in the safety and utility of this important class of vectors for use as vaccines or gene therapies
Adjuvants: Production of well-defined, tailor-made, non-toxic and thermostable adjuvants that can be combined with a wide range of antigens
Blood-brain barrier carriers: Development of carriers for delivering therapeutics beyond brain barriers
Related link(s)
Contact us
Kelley Parato
R&D Director
Biomanufacturing
Telephone: 343-548-6527
Email: Kelley.Parato@nrc-cnrc.gc.ca